SCHEMBL19785660

SCHEMBL19785660

CCc1nnc(Cn2c(=O)[nH]c3ccccc3c2=O)s1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.59
ALDH1A1 P00352 3/20 0.58
HPGD P15428 3/20 0.58
KDM4E B2RXH2 3/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
TSHR P16473 1/20 0.51
QPCT Q16769 1/20 0.47
MPO P05164 2/20 0.47
NPEPPS P55786 1/20 0.47
ADORA3 P0DMS8 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA2B P29275 1/20 0.46
ADORA1 P30542 1/20 0.46
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PARG Q86W56 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17824813 0.87 ALDH1A1 (0.58) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL9523849 0.76 CYP1A2 (1.00) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL6982894 0.74 HPGD (1.00) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL30877025 0.74 HPGD (1.00) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL17825074 0.73 PARG (0.57) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL8692730 0.73 CYP1A2 (0.76) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL19291210 0.71 HPGD (0.80) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL14560539 0.71 ALDH1A1 (0.73) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL11985495 0.71 CYP1A2 (0.67) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL6982033 0.70 ALDH1A1 (0.64) CYP1A2ALDH1A1HPGDKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-03-26 US disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG PARG, PARP15, PARP12 CYP1A2 323/4885ALDH1A1 1788/4885HPGD 233/4885
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG PARG, PARP15, PARP12 CYP1A2 323/4885ALDH1A1 1788/4885HPGD 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.